This Wiki is currently under construction
For the complete documentation index, see llms.txt. This page is also available as Markdown.

dibenzoylthiamine

Section: Complete Biochemistry → Thiamine Derivatives Reading level: Technical, with a plain-language summary Last reviewed: October 2026

Summary

O,S-Dibenzoylthiamine (DBT) is a thiamine derivative in which the ring-opened form of thiamine carries two benzoyl groups: one attached to the sulfur (a thioester) and one to the oxygen of the side chain (an ester). It was synthesized in Japan decades ago but received little attention until around 2020. Since then, researchers at the University of Liège and collaborators have studied it in cell cultures and mouse models.

In these studies, DBT raised thiamine levels and showed antioxidant and anti-inflammatory effects, which in vitro appeared at lower concentrations than benfotiamine. In a mouse model of ALS, DBT improved motor function and reduced muscle atrophy, while thiamine itself had little effect. These results are interesting, but they are entirely preclinical. No controlled human trials of DBT have been published as far as we could find, and human pharmacokinetic and long-term safety data are lacking.

Key facts

Property
Detail

Chemical name

O,S-Dibenzoylthiamine

Formula

C₂₆H₂₆N₄O₄S

Class

O,S-diacyl derivative (thioester plus ester)

Activation

Hydrolysis of the thioester and ester bonds → thiamine

Lipophilicity

Lipophilic

Research stage

Cell culture and rodent studies

Human trials

None published (as of October 2026, to our knowledge)

Chemistry and activation

Like benfotiamine, DBT is a thioester of the open thiol form of thiamine. Unlike benfotiamine, it has:

  • no phosphate group, so it does not need dephosphorylation before absorption;

  • a second benzoyl ester on the side-chain oxygen, which increases lipophilicity.

Inside the body, esterases and thioesterases remove the benzoyl groups. The resulting thiol form closes to thiamine, which is phosphorylated to TPP. The intermediate metabolites, including partially de-benzoylated forms, have not been fully characterized.

Preclinical findings

Cell studies

In cultured neuroblastoma cells and microglia, DBT:

  • increased intracellular thiamine compounds;

  • reduced markers of oxidative stress;

  • reduced inflammatory responses (for example, to bacterial lipopolysaccharide in microglia);

  • was effective at lower concentrations than benfotiamine in several assays.

Mouse studies

Model
Main findings
Reference

Stress and neurodegeneration models

Antioxidant and anti-inflammatory effects; improvements in behavioural measures

Sambon et al., 2020

FUS[1–359]-transgenic mice (ALS model), 6 weeks of treatment from the pre-symptomatic stage

DBT improved motor performance and physiological measures and reduced muscle atrophy. It normalized GSK-3β levels in brain and spinal cord and reduced spinal cord IL-1β expression. Serum metabolomic changes seen in untreated mutant mice were largely absent with DBT. Thiamine itself had little effect.

Probert et al., 2022

Proposed mechanisms

  • Increased thiamine and TPP delivery: DBT raises circulating thiamine more efficiently than thiamine salts.

  • TPP-independent effects: as with benfotiamine, some antioxidant and anti-inflammatory effects do not appear to be explained by TPP or TPP-dependent enzyme activity. Researchers have proposed that open-thiazole-ring metabolites may be responsible.

  • GSK-3β normalization: observed in the ALS model; the upstream mechanism is unknown.

These mechanisms have not been confirmed, and the active metabolites have not been identified.

What is not known

Interpreting the evidence

DBT is a scientifically interesting compound with a coherent preclinical rationale. However, many compounds that perform well in mouse models of neurodegeneration, particularly ALS models, have not translated into benefits for people. Until human pharmacokinetic, safety and efficacy studies are published, claims about DBT's effects in humans are unsupported. This applies to claims of benefit as much as to assumptions of harm.

Open questions

  • What are DBT's pharmacokinetics and brain penetration in humans?

  • Which metabolites mediate its effects, and are they shared with benfotiamine?

  • Will the effects seen in mouse models replicate in independent laboratories and in human trials?

  • Thiamine Derivatives (Overview)

  • Benfotiamine

  • Novel Derivatives & Future Research

  • Non-Coenzyme Roles

References

  1. Sambon M, Gorlova A, Demelenne A, et al. Dibenzoylthiamine has powerful antioxidant and anti-inflammatory properties in cultured cells and in mouse models of stress and neurodegeneration. Biomedicines. 2020;8(9):361.

  2. Sambon M, Wins P, Bettendorff L. Neuroprotective effects of thiamine and precursors with higher bioavailability: focus on benfotiamine and dibenzoylthiamine. International Journal of Molecular Sciences. 2021;22(11):5418.

  3. Probert F, Gorlova A, Deikin A, et al. In FUS[1–359]-tg mice O,S-dibenzoyl thiamine reduces muscle atrophy, decreases glycogen synthase kinase 3 beta, and normalizes the metabolome. Biomedicine & Pharmacotherapy. 2022;156:113986.

  4. [Authors to be confirmed]. Synthetic thioesters of thiamine: promising tools for slowing progression of neurodegenerative diseases. International Journal of Molecular Sciences. 2023;24(14):11296.


Editorial note: This page describes mechanisms and published evidence. It is not medical advice and does not recommend doses. Suggest corrections or new sources via the feedback link.

Was this helpful?